UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Investigational new drugs, 2014-10, Vol.32 (5), p.825-837

2014

Volltextzugriff (PDF)

Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

Cancer chemotherapy and pharmacology, 2013-03, Vol.71 (3), p.555-564

2013

Volltextzugriff (PDF)

Ruthenium-based chemotherapeutics: are they ready for prime time

Cancer chemotherapy and pharmacology, 2010-05, Vol.66 (1), p.1-9

2010

Volltextzugriff (PDF)

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Cancer chemotherapy and pharmacology, 2012-04, Vol.69 (4), p.901-909

2012

Volltextzugriff (PDF)

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Cancer chemotherapy and pharmacology, 2013-04, Vol.71 (4), p.829-842

Burris, Howard A.

2013

Volltextzugriff (PDF)

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Cancer chemotherapy and pharmacology, 2014-11, Vol.74 (5), p.1023-1028

2014

Volltextzugriff (PDF)

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Advances in therapy, 2013-10, Vol.30 (10), p.870-884

2013

Volltextzugriff (PDF)

Development of artemisinin compounds for cancer treatment

Investigational new drugs, 2013-02, Vol.31 (1), p.230-246

2013

Volltextzugriff (PDF)

A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis

Cancer chemotherapy and pharmacology, 2013-05, Vol.71 (5), p.1115-1130

2013

Volltextzugriff (PDF)

Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats

Cancer chemotherapy and pharmacology, 2011-09, Vol.68 (3), p.593-601

2011

Volltextzugriff (PDF)

Pathogenesis and Treatment of Impaired Wound Healing in Diabetes Mellitus: New Insights

Advances in therapy, 2014-08, Vol.31 (8), p.817-836

2014

Volltextzugriff (PDF)

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Investigational new drugs, 2014-02, Vol.32 (1), p.178-187

2014

Volltextzugriff (PDF)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

2012

Volltextzugriff (PDF)

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2013-02, Vol.71 (2), p.523-530

2013

Volltextzugriff (PDF)

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

Cancer chemotherapy and pharmacology, 2012-09, Vol.70 (3), p.399-405

2012

Volltextzugriff (PDF)

2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.899-910

2011

Volltextzugriff (PDF)

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

Cancer chemotherapy and pharmacology, 2010-07, Vol.66 (2), p.357-371

2010

Volltextzugriff (PDF)

A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer

Cancer chemotherapy and pharmacology, 2011-07, Vol.68 (1), p.157-164

2011

Volltextzugriff (PDF)

novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells

Cancer chemotherapy and pharmacology, 2010-08, Vol.66 (3), p.535-545

2010

Volltextzugriff (PDF)

Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial

Cancer chemotherapy and pharmacology, 2013-03, Vol.71 (3), p.765-775

2013

Volltextzugriff (PDF)

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

Investigational new drugs, 2013-08, Vol.31 (4), p.1071-1077

2013

Volltextzugriff (PDF)

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

Investigational new drugs, 2014-12, Vol.32 (6), p.1246-1257

2014

Volltextzugriff (PDF)

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

Cancer chemotherapy and pharmacology, 2013-06, Vol.71 (6), p.1395-1409

Britten, Carolyn D.

2013

Volltextzugriff (PDF)

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2014-08, Vol.32 (4), p.670-681

2014

Volltextzugriff (PDF)

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer

Journal of cancer research and clinical oncology, 2013-12, Vol.139 (12), p.2133-2140

2013

Volltextzugriff (PDF)

1 – 25 von 12.548

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Immunology And Immunotherapy

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12.548)
Mit Volltextzugriff
(12.516)

Publikationsform

Artikel
(12.547)
Tagungsberichte
(1)

Sprache

Englisch
(12.548)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12.327)
Life Sciences & Biomedicine
(12.326)
Humans
(10.746)
Biological And Medical Sciences
(10.442)
Medical Sciences
(10.442)
Pharmacology. Drug Treatments
(10.280)
Antineoplastic Agents
(9.006)
Pharmacology & Pharmacy
(7.614)
Female
(7.520)
Male
(6.082)
Medicine
(5.682)
Medicine & Public Health
(5.671)
Middle Aged
(5.653)
Aged
(4.918)
Adult
(4.621)
Chemotherapy
(4.512)
Cancer Research
(4.447)
Pharmacology/toxicology
(3.660)
Tumors
(3.532)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

Ruthenium-based chemotherapeutics: are they ready for prime time

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Development of artemisinin compounds for cancer treatment

A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis

Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats

Pathogenesis and Treatment of Impaired Wound Healing in Diabetes Mellitus: New Insights

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer

novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells

Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer

Aktive Filter

Suchergebnisse filtern